Bone Repair Articles & Analysis
17 news found
She earned her Bachelor of Science degree in biomedical engineering from the University of Iowa and is an inventor on a U.S. patent for a bone plate system for repair of proximal humeral fracture. “It is an exciting time to be joining Daxor as we prepare to submit our next generation systems in preparation for the most important technology launch for the ...
Several peptides have been shown to support and stimulate the bone healing response and have been proposed as therapeutic vehicles for clinical use. ...
BELLEVUE, Wash., Oct. 6, 2022 – CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced participation in the Industry Sessions of the Orthopaedic Trauma Association (OTA) 38th Annual Meeting, Oct. 12-15 in Tampa, Fl, highlighting the expanding use of the CurvaFix® IM Implant by industry-leading surgeons for ...
BELLEVUE, Wash., Sept. 28, 2022 – CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the addition of three new members to its Surgeon Advisory Board. ...
This experiment will examine the biomaterial's osteoconductivity when used in a microgravity environment where bone density and the ability to regenerate new bone tissue is significantly compromised. ...
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD). ...
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, announced today the completion of enrollment of the ASPIRE study, a pivotal U.S. ...
Since the last few decades, biomedical materials have been extensively used in a lot of medical applications, such as tissue scaffolds, wound care, regenerative dentistry, bone graft, implantable devices and cosmetic surgery. Earlier this month, T,C&A Lab, a branch of Alfa Chemistry, announces to provide biomedical material testing service for customers worldwide who would ...
It is intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect and is anticipated to be available for clinical use in 2023. The company is also working on silk technologies focused on vascular grafting, rotator cuff repair, bone grafting and drug release which they plan to launch between ...
ByKLISBio
Cerapedics Inc., a private ortho-biologics company dedicated to enhancing the science of bone repair, announced today that results of a study to evaluate the cost-effectiveness of i-FACTOR Peptide Enhanced Bone Graft compared to autograft for patients undergoing ACDF surgery were recently published in ClinicoEconomics and Outcomes Research (July ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™ ...
Not only is this traumatic to the dog and its owner, but it is also expensive costing between $2,000 to $5,000 based on regional pricing differences." RevBio identified that its bone adhesive biomaterial could be used to fill the extraction sockets in the alveolar ridges of dogs. ...
Currently, the standard treatment for chronic osteomyelitis is surgical debridement, long-term, high-dose administration of antibiotics, and – for larger defects – bone grafting which often requires a second surgical procedure to remove the non-resorbable bone graft. CognitOss is intended to offer surgeons a single surgical procedure alternative, ...
Its new name, RevBio, was chosen since it more accurately portrays the objective of developing its revolutionary Tetranite® bone adhesive biomaterial platform. The company has also adapted a tag line "Transforming Bone Repair" which better defines the company's musculoskeletal focus in developing products for both dental and orthopedic ...
-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth using ZetaMet™ New patent further enhances the Company’s Global IP strategy Zetagen Therapeutics, Inc., a private, US-based ...
” Regenerative Medicine holds great promise to provide effective therapies for non-healing large cartilage and bone defects, which remain unmet medical needs. When the environment is compromised, such as in long standing non-union fractures, in the presence of other co-morbidities, such as diabetes and in the aging patient, the endogenous repair potential ...
ByPoietis
Ankasa is focusing on the development of the stem cell growth factor WNT3A, which is found in humans and functions in the maintenance of bone growth and repair, but the level of which declines with age. Ankasa intends to initially develop a proprietary localized therapy involving WNT3A for spinal fusion surgery patients. ...